On January 27, 2023 the U.S. Food and Drug Administration (FDA) announced it has approved pirtobrutinib (Jaypirca, Eli Lilly and Company), for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.

“The approval of pirtobrutinib represents an important advancement for the treatment of relapsed/refractory mantle cell lymphoma,” said Meghan Gutierrez, Chief Executive Officer of the Lymphoma Research Foundation. “Expanded treatment options can transform the patient experience and provide hope to people living with a mantle cell diagnosis

For more information on the FDA approval of pirtobrutinib (Jaypirca, Eli Lilly and Company), visit the FDA’s website.  To learn more about treatment options for MCL, visit the MCL learning center.